Shares of Cytokinetics CYTK moved lower in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 26.47% over the past year to ($0.86), which missed the estimate of ($0.65).
Revenue of $2,843,000 decreased by 20.87% from the same period last year, which missed the estimate of $5,450,000.
Guidance
Cytokinetics Sees FY21 Sales $23M-$28M Vs. $28.07M Est.
Conference Call Details
Date: Aug 05, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/6937pskr
Recent Stock Performance
52-week high: $31.41
Company's 52-week low was at $14.71
Price action over last quarter: Up 24.80%
Company Description
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
